drugset
drugset / Trial / NCT07665073

Risperidone vs Cariprazine in Acute Mania

NCT07665073 ↗

Phase 4 Not yet recruiting 50 enrolled Pakistan Institute of Medical Sciences
RandomizedParallel-groupDouble-blindTreatment

Summary

Randomized, double-blind, parallel-group study comparing efficacy and safety of Risperidone versus Cariprazine in adults with acute manic episodes. Participants will receive oral study drug for 6 weeks. Primary outcome is change in YMRS total score from baseline to week 6.

Timeline

Start
2027-06
Primary completion
2028-06
Completion
2028-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cariprazine Small molecule 1.5 mg Oral
Comparator Cariprazine Small molecule 6 mg Oral
Subject Risperidone Other / unclassified 2 mg Oral
Subject Risperidone Other / unclassified 6 mg Oral

Indications

bipolar I disorder